Vicarious Surgical Plans to Shut Down Next Week as Cash Runs Out
The Massachusetts surgical robotics company has asked shareholders to vote on dissolving the business on July 21. Investors are unlikely to receive anything back.
Key points
- Vicarious Surgical's board scheduled a shareholder vote on July 21, 2025 to dissolve and liquidate the company.
- The company held just under $3.7 million in cash as of March 31, 2025, against $9 million in total liabilities.
- Vicarious Surgical lost $7.3 million in the first quarter of 2025, following a $50.2 million loss across the full year of 2025.
- CEO Stephen From, President Adam Sachs, and CTO Sammy Khalifa are set to receive a combined minimum of roughly $1.36 million in severance pay.
- The board says ordinary shareholders are unlikely to recover any money.
Vicarious Surgical, a Waltham, Massachusetts company that spent years developing robots to assist with soft-tissue surgery (operations on organs and tissue rather than bone), is preparing to close as soon as next week.
A special shareholder meeting is set for July 21. Approve a plan to wind the company down, sell off its assets, and pay creditors: that's all shareholders are being asked to decide. Executives and directors together control 55% of the voting power, so the outcome is nearly certain.
The board didn't soften the warning to investors. "Based upon our current outstanding liabilities, it is unlikely you will receive any distribution," it wrote in a securities filing, a formal document companies must submit to financial regulators.
The numbers are blunt. Just under $3.7 million in cash at the end of March, against a quarterly burn of $7.3 million. A $50.2 million loss across 2025, and $63 million the year before. No buyer came forward. "We have been unable to secure additional equity or other financing and have been unsuccessful in our efforts to attract a buyer for our business," the company said in the filing.
The Robot Report, which first reported on the shareholder meeting, noted that surgical robotics analyst Steve Bell flagged an upcoming asset auction on LinkedIn, calling it "the end of the road for another interesting soft tissue robot."
What does this mean for the people who worked there?
As of March, Vicarious employed 26 people across research, manufacturing, and administration. Those jobs are gone once the vote passes.
Three senior executives will receive severance: CEO Stephen From gets at least $500,000, co-founder and President Adam Sachs at least $541,620, and CTO Sammy Khalifa at least $318,600. All three also receive partial bonus payments and health insurance continuation. Their contracts were amended in the first quarter of 2026.
CFO Sarah Romano had already resigned, taking the same role at SS Innovations effective August 3.
This closure isn't a bankruptcy filing. The board chose a state-level assignment process instead, arguing it gives creditors a better shot at recovering money than federal bankruptcy proceedings would.
Should investors in smaller surgical robotics firms pay attention?
For patients and hospitals, the immediate impact is limited since Vicarious Surgical's robot never reached commercial use. The collapse does show how unforgiving the path from prototype to operating room really is. Intuitive Surgical and Medtronic reached scale over decades with capital that smaller entrants simply can't match. AI2Day has covered the funding extremes at both ends of the robotics market this month: a Chinese firm raised $735 million on the same day we launched, while this story sits at the other end of the ledger. What gets oversold is the idea that a compelling prototype buys runway; what to watch next is whether Vicarious Surgical's IP auction attracts any of the larger players looking for a shortcut into soft-tissue robotics.
